The NC3Rs has an annual budget of around £10 million. We receive core funding from the Medical Research Council (MRC) and the Biotechnology and Biological Sciences Research Council (BBSRC), which are part of UK Research and Innovation.
We also receive funding for specific programmes from the charitable and commercial sectors, and co-funding from other research funders. In 2017/18, this included the following organisations:
Association of the British Pharmaceutical Industry (ABPI)1
|Alzheimer's Research UK|
|British Heart Foundation (BHF)|
|Defence Science and Technology Laboratory (DSTL)|
|Engineering and Physical Sciences Research Council (EPSRC)|
|The Dow Chemical Company|
1 in accordance with the ABPI's Code of Practice regulating the pharmaceutical industry, the following companies have provided funding to the NC3Rs as part of the ABPI-NC3Rs collaboration: AstraZeneca, Covance Laboratories, Eli Lily & Company, GlaxoSmithKline, Huntingdon Life Sciences, Novartis Pharmaceuticals, Pfizer, Shire Pharmaceutical Development, Takeda Cambridge and UCB Pharma.